Literature DB >> 20546860

Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma.

Yu-Cai Wang1, Lian-He Zheng, Bao-An Ma, Yong Zhou, Ming-Hua Zhang, Dian-Zhong Zhang, Qing-Yu Fan.   

Abstract

The dysregulation of signal transducers and activators of transcription 3 (STAT3) has been reported to be associated with tumor progression, angiogenesis and metastasis. The purpose of this study was to analyze the clinical value of STAT3 expression in human osteosarcoma. First, semi-quantitative RT-PCR was performed to detect the expression of STAT3 mRNA in normal bone tissues, chondroma tissues and osteosarcoma tissues. Then, immunohistochemistry was performed to detect the expression of STAT3 protein in 76 osteosarcoma tissues and the relationship of STAT3 protein expression with clinicopathologic factors or prognosis of osteosarcoma patients. RNA interference (RNAi) technology was employed to inhibit STAT3 expression. MTT and flow cytometric assays were performed to analyze the effect of STAT3 inhibition on proliferation and apoptosis of osteosarcoma cells. Finally, the expression of STAT3-related target genes were also determined. Results showed that osteosarcoma tissues showed significantly higher expression levels of STAT3 mRNA than normal bone or chondroma tissues (P<0.05). Immunohistochemistry showed that the staining of STAT3 protein was mainly located in cytoplasm of osteosarcoma cells in osteosarcoma tissue samples. The high level of STAT3 protein was associated with poor tumor differentiation and presentation of metastasis (P=0.039 and 0.022). Moreover, the 5-year overall and relapse-free survival rates for osteosarcoma patients with high STAT3 expression were lower than those for patients with low STAT3 expression. In addition, the status of STAT3 protein expression was an independent prognostic factor for both disease-free survival (P=0.0235) and overall survival (P=0.0032). RNAi-mediated STAT3 inhibition could induce proliferation inhibition and apoptosis enhancement in osteosarcoma cells, which might be associated with inhibition of some anti-apoptosis genes. Overall, STAT3 plays crucial roles in osteosarcoma development and might become a potential molecular target for gene therapy of human osteosarcomas.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20546860     DOI: 10.1016/j.acthis.2010.03.002

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  18 in total

1.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

2.  Upregulation of a disintegrin and metalloprotease 8 influences tumor metastasis and prognosis in patients with osteosarcoma.

Authors:  Zhehai Li; Qiande Liao; Yuchi Wu; Mingmei Liao; Yuqin Hao; Shengbin Zhang; Shipeng Song; Bing Li; Yang-de Zhang
Journal:  Pathol Oncol Res       Date:  2012-01-05       Impact factor: 3.201

3.  Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: a meta-analysis of literatures.

Authors:  Hongyu Kong; Qiongwen Zhang; Yunhui Zeng; Hong Wang; Mengqian Wu; Tianying Zheng; Yanzhang Zeng; Huashan Shi
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.

Authors:  Stacey L Fossey; Misty D Bear; Jiayuh Lin; Chenglong Li; Eric B Schwartz; Pui-Kai Li; James R Fuchs; Joelle Fenger; William C Kisseberth; Cheryl A London
Journal:  BMC Cancer       Date:  2011-03-28       Impact factor: 4.430

5.  Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.

Authors:  Stacey L Fossey; Misty D Bear; William C Kisseberth; Michael Pennell; Cheryl A London
Journal:  BMC Cancer       Date:  2011-04-11       Impact factor: 4.430

6.  Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma.

Authors:  Sébastien Salas; Carine Jiguet-Jiglaire; Loic Campion; Catherine Bartoli; Frédéric Frassineti; Jean-Laurent Deville; André Maues De Paula; Fabien Forest; Pascal Jézéquel; Jean-Claude Gentet; Corinne Bouvier
Journal:  BMC Cancer       Date:  2014-08-20       Impact factor: 4.430

7.  An integrative analysis of DNA methylation in osteosarcoma.

Authors:  Jie Xu; Deng Li; Zhiqing Cai; Yingbin Zhang; Yulin Huang; Baohua Su; Ruofan Ma
Journal:  J Bone Oncol       Date:  2017-05-19       Impact factor: 4.072

8.  Exploring the molecular mechanisms of osteosarcoma by the integrated analysis of mRNAs and miRNA microarrays.

Authors:  Hao Shen; Wei Wang; Bingbing Ni; Qiang Zou; Hua Lu; Zhanchao Wang
Journal:  Int J Mol Med       Date:  2018-03-27       Impact factor: 4.101

9.  Genetic Interactions of STAT3 and Anticancer Drug Development.

Authors:  Bingliang Fang
Journal:  Cancers (Basel)       Date:  2014-03-06       Impact factor: 6.639

Review 10.  Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis.

Authors:  Pin Wu; Dang Wu; Lufeng Zhao; Lijian Huang; Gang Shen; Jian Huang; Ying Chai
Journal:  Oncotarget       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.